Testing of GripTract-GI Endoscopic Tissue Manipulator for Use During Complex Endoscopic Polypectomies in the Colon

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age21+
SponsorActuated Medical, Inc.

About this trial

The goal of this clinical trial is to compare the safety and effectiveness of the GripTract GI Endoscopic Tissue Manipulator to the current standard of care for complex polypectomies in adults. The main questions it aims to answer are:

1. How does the number and severity of Device-Attributable Adverse Events compare to the current standard of care? 2. How is the procedure time affected? 3. Is the ability to resect the tissue en bloc affected? 4. What is the user feedback on the device performance?

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients scheduled for endoscopic removal of suspected adenomatous benign polyps(s)

Patients capable of giving informed consent English and lacking cognitive impairment

No medical contraindication to endoscopic mucosal resection or endoscopic submucosal dissection

Disqualifiers

Patients less than 21 years of age

Any contraindication to colonoscopy with due to subject's colon anatomy (i.e., structure)

History of open or laparoscopic colorectal surgery

History of Inflammatory Bowel Disease

Trial design

Design model

Parallel

Treatments tested in this trial

  • Control (via ESD using standard of care)

    Device

    Polyp removal via ESD using standard of care

  • GripTract

    Device

    Polyp removal via ESD using GripTract

Treatment groups

30 Participants
are divided into 2 treatment groups
Group A: ControlActive comparator 1 intervention
Group B: GripTractExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Total Number of Device-Attributable Major Adverse Events

Subjects will receive follow-ups at 24 hrs, 72 hours, and 30 days post intervention to monitor adverse events. Major adverse events are those that necessitate non-endoscopic intervention.

Time frame
Enrollment to 30 days
2

Total Number of Device-Attributable Minor Adverse Events

Subjects will receive follow-ups at 24 hrs, 72 hrs, and 30 days post intervention to monitor adverse events. Minor adverse events are those that can be successfully addressed endoscopically.

Time frame
Enrollment to 30 days

Secondary outcomes

1

Total Intervention Time

Total Intervention Time from the start of submucosal injection through the end of dissection.

Time frame
4 hours
2

Dissection Time

Time from first incision of polyp removal (following circumferential incision) through end of polyp removal.

Time frame
3 hours
3

Area of tissue removed

Dimensional measurement of resected tissue

Time frame
4 hours
4

En bloc removal

Clinician peforming procedure provides a binary score: lesion removed en bloc, or lesion NOT removed en bloc

Time frame
4 hours

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Actuated Medical, Inc.

Lead sponsor

National Institutes of Health (NIH)

Collaborator